| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
The prognosis of patients with osteosarcoma has not improved over the last 30 years. In this study, we examined the metastasis-promoting effect of lung fibrosis in metastatic lesions and its potential as a therapeutic target in lung metastasis of osteosarcoma. We confirmed that lung fibrosis with activated fibroblasts progressed with the lung metastasis of osteosarcoma and that lung fibrosis in a bleomycin model promoted lung metastasis of osteosarcoma. The proliferation of osteosarcoma cells was dependent on the amount of collagen fiber on soft polyacrylamide gels. Anti-fibrotic agents significantly suppressed lung metastasis in a mouse model of osteosarcoma lung metastasis. Anti-fibrotic agents may effectively suppress lung metastasis of osteosarcoma, which has low adaptability to soft environments.
|
